Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22678610 | 1.00 | ALDH1A1 (0.65) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22712499 | 0.88 | ALDH1A1 (0.67) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22658054 | 0.85 | NPC1 (0.56) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4384415 | 0.80 | SMN1; SMN2 (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL28581423 | 0.80 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29409952 | 0.79 | XDH (0.56) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22658090 | 0.79 | XDH (0.56) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22658073 | 0.79 | HDAC4 (0.50) | ALDH1A1KDM4EXDHMEN1KMT2A | |
| SCHEMBL403150 | 0.78 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL28699403 | 0.78 | XDH (0.47) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025066915-A1 | AHR MODULATOR AND USE THEREOF | 德明药泰生物技术（深圳）有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119707643-A | AhR regulator and application thereof | 德明药泰生物技术（深圳）有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119343340-A | Methods of preparing modified BTK inhibitors | 普林斯匹亚生物制药公司 | 2025-01-21 | — | — | CN | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-115960074-A | Fluorine-containing ferroelectric liquid crystal molecules containing heteroatom hexatomic alicyclic ring and synthesis method thereof | 华南理工大学 | 2023-04-14 | — | — | CN | disclosed |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| CN-114127049-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | ALDH1A1 1085/4885NPC1 3240/4885RAB9A 129/4885 |
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | ALDH1A1 3979/4885NPC1 3009/4885RAB9A 731/4885 |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | ALDH1A1 347/4885NPC1 3336/4885RAB9A 2607/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | ALDH1A1 1085/4885NPC1 3240/4885RAB9A 129/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | ALDH1A1 347/4885NPC1 3336/4885RAB9A 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.